Diadem SpA i aso nei na faasilasilaina le tapunia o le vaega muamua o le € 10 miliona faʻatupeina tutusa. O le ta'amilosaga fa'atupe o lo'o ta'ita'ia e le CDP Venture Capital fou ma fai pisinisi a Panakès Partners. O le faʻatupega fou na mulimuli mai i le faʻasalalauga i le amataga o lenei masina e le Diadem ma le European Investment Bank (EIB) na tuʻuina atu e le EIB ia Diadem se nonogatupe 7.5 miliona Euro.
O le a faʻaaogaina e Diadem le faʻatupega fou e faʻaauau ai le faʻasalalauga faʻavaomalo ma le faʻamaonia atili o le falemaʻi o lana AlzoSure® Predict, o se suʻega toto e le faʻaleagaina e mafai ona iloa ma le saʻo maualuga pe o tagata i luga atu o le 50 tausaga o loʻo iai faʻailoga o le faʻaleagaina o le mafaufau o le a pe leai. alualu i luma i le fa'ama'i o le Alzheimer e o'o atu i le ono tausaga a'o le'i aliali mai fa'ailoga mautinoa. O lona aoga o loʻo lagolagoina e faʻamatalaga faʻapitoa mai se suʻesuʻega umi umi lea na avea ma faʻavae mo AlzoSure® Predict's talu ai nei na maua ai se faʻailoga CE-IVD ma se faʻailoga Breakthrough Device mai le US Food & Drug Administration.
"Diadem o se faʻataʻitaʻiga sili ona lelei o atinaʻe fou: o se tekonolosi tulaga ese, na atiina ae i le Iunivesite o Brescia, o se nofoaga autu suʻesuʻe maualuga, ma ofoina atu le avanoa e faʻalavelave ai i le amataga lava o le pathological process, pe a oʻo i le avanoa e manuia ai le faʻalavelave. e sili atu, ”o le tala lea a Enrico Resmini, Pule Sili ma Pule Sili o le CDP Venture Capital. "Matou te matua faamalieina i la matou tupe teufaafaigaluega i Diadem, lea e fetaui ma a matou tulaga o aʻafiaga lautele ma faʻaosofiaga o suʻesuʻega i le vaega o le soifua maloloina."
Na taʻua e Diana Saraceni, Founder ma Managing Partner of Panakes Partners, "Matou te fiafia e toe faafou a matou tupe teufaafaigaluega i Diadem, o ana tekinolosi fou e mafai ona suia ai le puleaina o le faʻamaʻi o le Alzheimer, o se tulaga faʻaleagaina ma le tele o tau i le tagata ma le sosaiete. . Ua tele le alualu i luma o le Diadem i le faʻalauteleina o ana tekonolosi AlzoSure talu mai le matou uluai faʻafaigaluegaina, faʻatupuina faʻamaonia faʻamaonia faʻamaumauga faʻapitoa, atinaʻeina o se oloa faʻatau pisinisi, mauaina o tusipasi taua ma faʻailoga, ma fausia se faʻavae mo pisinisi faʻatauvaʻa manuia faʻatasi ma paaga faʻapitoa. Ua tula'i mai o se ta'ita'i i le vaega taua o su'esu'ega fou o le biomarker, ma ua matou mitamita ai e ta'ita'ia lenei taamilosaga tau tupe.
"Matou te faʻafeiloaʻi le lagolago a nei vaega faʻapitoa faʻapisinisi, o loʻo faʻasoa la matou vaʻaiga i se lalolagi lea o faʻailoga vave o le faʻaleagaina o le mafaufau o se valaau e faʻatino, ae le o se faʻasalaga oti," o le tala lea a Dr. Gerald Möller, Taitaifono o le Komiti Faatino o Diadem. . "I lalo o le taʻitaʻiga faʻapitoa a Paul Kinnon, o le a faʻaaogaina e Diadem ia tupe e faʻalautele atili ai le faʻalapotopotoga a le kamupani i le lalolagi atoa e lagolago ai a matou suʻesuʻega faʻapitoa faʻataʻitaʻiga e mafai ona faʻafouina le faʻamaʻi o le Alzheimer. O lenei fa'atupega fa'atasi ma le maliega fa'aunegatupe a le EIB na fa'asalalau talu ai nei o le a maua ai e Diadem le laumua e lagolago ai le kamupani a'o fa'atauina AlzoSure® Predict ma fausia ai se atina'e manuia i le lalolagi.
O lo'o fa'atupuina e le Diadem le su'esu'ega a le AlzoSure® Predict o se su'ega fa'ata'ita'i fa'ata'ita'i fa'atatau i le plasma faigofie e le fa'asa'o e va'ai sa'o ai le fa'amoemoe o se tagata ma'i e silia ma le 50 tausaga ma fa'aletonu le mafaufau o le a aga'i atu i le Alzheimer's dementia. O tekinolosi a le kamupani o loʻo faʻaaogaina se metotia suʻesuʻe e aofia ai se antibody pateni na atiaʻe e Diadem ma fuafuaina e fusifusia i le U-p53AZ ma ona faʻasologa faʻasologa. U-p53AZ o se faʻasologa faʻasologa o le p53 protein lea na aʻafia i le pathogenesis o le AD i le tele o suʻesuʻega.
Mo le CDP Venture Capital, o le taʻaloga na vaʻaia e Mario Scuderi ma Gregorio Gaspari, o le pule faʻatasi ma le suʻega o le Evolution Fund.
OA MEA E AVEA MAI LENEI TUSI:
- a unique technology, developed at the University of Brescia, an advanced research center, and offering the opportunity of intervening in the very early stages of the pathological process, when the chances of success of the intervention are greater,”.
- Diadem will use the new funding to continue the global commercialisation and further clinical validation of its AlzoSure® Predict, a non-invasive biomarker blood test that can identify with high accuracy whether individuals over the age of 50 with signs of cognitive impairment will or will not progress to Alzheimer’s disease up to six years before definitive symptoms are apparent.
- This funding in conjunction with the recently announced EIB loan agreement will provide Diadem with the capital to support the company as it commercialises AlzoSure® Predict and builds a successful global enterprise.
